Precipio Inc (PRPO)

[laser777]

Progression of positive news.

The 2 news items were extremely significant this week.
The licensing agreement with the University of Melbourne comes after nearly a year of validation.

The first commercial license follows a 2014 research agreement between Transgenomic and the University of Melbourne for the conduct of clinical validation studies of the MX-ICP technology.

http://finance.yahoo.com/news/transgenomic-university-melbourne-collaborate-further-110000143.html

This is the first validation that this liquid biopsy works and was validated by University research.

Prof. Paul Waring, Chair of Pathology at the University of Melbourne, Head of Molecular Pathology at Melbourne Health and Director of the Centre for Translational Pathology at Melbourne University, commented, “We have been working with the MX-ICP liquid biopsy technology for about a year and have been very favorably impressed with its accuracy, exceptional sensitivity and overall utility. We are delighted we will now be able to put it to work for our cancer patients and, in partnership with Transgenomic, to drug developers here in Australia.”

Paul Kinnon, President and Chief Executive Officer of Transgenomic, noted “The University of Melbourne and Prof. Waring are recognized leaders in molecular pathology and cancer genomics, so we are especially pleased to award this first commercial MX-ICP license to them for use in Australia. Melbourne University is an innovator in patient care and cancer treatment, and the agreement has the added benefit of providing us with the opportunity for additional validation of our MX-ICP technology and our new liquid biopsy diagnostic assays in partnership with a top tier cancer institution. This is the first of what we expect to be many licenses worldwide for our MX-ICP technology.”